Novo Nordisk Gross Profit 2010-2022 | NVO

Novo Nordisk annual/quarterly gross profit history and growth rate from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Novo Nordisk gross profit for the quarter ending December 31, 2022 was $5.509B, a 11.21% increase year-over-year.
  • Novo Nordisk gross profit for the twelve months ending December 31, 2022 was $21.028B, a 12.83% increase year-over-year.
  • Novo Nordisk annual gross profit for 2022 was $21.028B, a 12.83% increase from 2021.
  • Novo Nordisk annual gross profit for 2021 was $18.637B, a 14.75% increase from 2020.
  • Novo Nordisk annual gross profit for 2020 was $16.241B, a 6.29% increase from 2019.
Novo Nordisk Annual Gross Profit
(Millions of US $)
2022 $21,028
2021 $18,637
2020 $16,241
2019 $15,280
2018 $14,405
2017 $14,288
2016 $14,057
2015 $13,651
2014 $13,238
2013 $12,366
2012 $11,156
2011 $10,047
2010 $8,754
2009 $7,612
Novo Nordisk Quarterly Gross Profit
(Millions of US $)
2022-12-31 $5,509
2022-09-30 $5,191
2022-06-30 $5,033
2022-03-31 $5,295
2021-12-31 $4,954
2021-09-30 $4,689
2021-06-30 $4,457
2021-03-31 $4,538
2020-12-31 $4,260
2020-09-30 $4,046
2020-06-30 $3,727
2020-03-31 $4,208
2019-12-31 $3,994
2019-09-30 $3,755
2019-06-30 $3,793
2019-03-31 $3,738
2018-12-31 $3,319
2018-09-30 $3,642
2018-06-30 $3,691
2018-03-31 $3,753
2017-12-31 $3,704
2017-09-30 $3,530
2017-06-30 $3,583
2017-03-31 $3,470
2016-12-31 $3,569
2016-09-30 $3,533
2016-06-30 $3,557
2016-03-31 $3,398
2015-12-31 $3,558
2015-09-30 $3,421
2015-06-30 $3,438
2015-03-31 $3,233
2014-12-31 $3,486
2014-09-30 $3,350
2014-06-30 $3,301
2014-03-31 $3,100
2013-12-31 $3,335
2013-09-30 $3,017
2013-06-30 $3,114
2013-03-31 $2,900
2012-12-31 $3,104
2012-09-30 $2,750
2012-06-30 $2,772
2012-03-31 $2,530
2011-12-31 $2,646
2011-09-30 $2,475
2011-06-30 $2,490
2011-03-31 $2,306
2010-12-31 $2,411
2010-09-30 $2,398
2010-06-30 $2,213
2010-03-31 $1,951
2009-12-31 $2,063
2009-09-30 $1,968
2009-06-30 $1,902
2009-03-31 $1,784
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $309.551B $25.059B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $430.370B 16.20
Eli Lilly (LLY) United States $322.186B 42.71
Merck (MRK) United States $260.994B 13.76
AbbVie (ABBV) United States $256.783B 10.65
Pfizer (PFE) United States $247.323B 6.70
Novartis AG (NVS) Switzerland $189.952B 14.05